Mereo BioPharma Group plc

Ultragenyx Pharmaceutical and Mereo BioPharma remain upbeat about the prospects for setrusumab despite the news that a pivotal trial of the bone disease candidate will not be stopped early for efficac

The ultra-rare disease specialist Ultragenyx is approaching several important catalysts this year, including US Food and Drug Administration action on UX111 – the firm’s first gene therapy, which targ

British science is often held up as a shining light: both a source of national pride thanks to the country’s huge contributions in the past, and a crucial part of the economy which should help drive g

Ultragenyx Pharmaceutical Inc. unveiled positive 14-month data on 11 June from the Phase II portion of a potentially registrational trial of setrusumab in osteogenesis imperfecta (OI), which multiple